Scarica l'app Stockscreener
39.61
1.18%
-0.38
Dopo l'orario di chiusura:
39.61
Precedente Chiudi:
$39.99
Aprire:
$39.99
Volume 24 ore:
474.86K
Relative Volume:
1.05
Capitalizzazione di mercato:
$1.25B
Reddito:
$757.07M
Utile/perdita netta:
$58.44M
Rapporto P/E:
24.65
EPS:
1.6068
Flusso di cassa netto:
$289.30M
1 W Prestazione:
-13.62%
1M Prestazione:
-17.97%
6M Prestazione:
+0.74%
1 anno Prestazione:
+40.94%
Intervallo 1D:
$39.18
$40.13
Intervallo di 1 settimana:
$39.18
$45.18
Portata 52W:
$23.23
$50.79
Collegium Pharmaceutical Inc Stock (COLL) Company Profile
Nome
Collegium Pharmaceutical Inc
Settore
Telefono
781-713-3699
Indirizzo
100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA
Compare COLL vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
COLL
Collegium Pharmaceutical Inc
|
39.61 | 1.26B | 757.07M | 58.44M | 289.30M | 1.6068 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.96 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.47 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-01-10 | Aggiornamento | Needham | Hold → Buy |
| 2024-07-30 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-06-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-05-10 | Downgrade | Needham | Buy → Hold |
| 2024-05-10 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-01-04 | Downgrade | Jefferies | Buy → Hold |
| 2023-08-25 | Reiterato | Needham | Buy |
| 2023-05-02 | Ripresa | Jefferies | Buy |
| 2022-08-08 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-02-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2021-08-06 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-01-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-14 | Iniziato | BWS Financial | Sell |
| 2020-05-27 | Iniziato | Guggenheim | Neutral |
| 2020-02-19 | Ripresa | Jefferies | Buy |
| 2019-10-30 | Reiterato | Needham | Buy |
| 2019-05-03 | Ripresa | H.C. Wainwright | Buy |
| 2019-04-12 | Ripresa | Janney | Buy |
| 2019-03-20 | Iniziato | SunTrust | Hold |
| 2019-01-16 | Reiterato | Needham | Buy |
| 2018-03-08 | Reiterato | H.C. Wainwright | Buy |
| 2018-02-07 | Reiterato | Needham | Buy |
| 2017-12-05 | Reiterato | Needham | Buy |
| 2017-09-11 | Iniziato | H.C. Wainwright | Buy |
| 2017-05-11 | Reiterato | Needham | Buy |
| 2016-09-13 | Iniziato | Gabelli & Co | Buy |
| 2015-06-01 | Iniziato | Jefferies | Buy |
| 2015-06-01 | Iniziato | Needham | Buy |
| 2015-06-01 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Collegium Pharmaceutical Inc Borsa (COLL) Ultime notizie
49,976 COLL shares flagged for sale (NASDAQ: COLL) - Stock Titan
Collegium, Paris Hilton announce ‘Embrace Your Sparkle’ campaign - TipRanks
Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community (2026-03-03) - Seeking Alpha
Collegium Pharmaceutical Faces Weak Start with 8.74% Gap Down Amid Market Concerns - Markets Mojo
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Momentum Shift: Does Collegium Pharmaceutical Inc offer margin of safety2025 Pullback Review & Weekly High Return Stock Forecasts - baoquankhu1.vn
Can Collegium Pharmaceutical Inc be the next market leaderMarket Growth Report & Reliable Price Breakout Signals - baoquankhu1.vn
Collegium to Participate in Upcoming Investor Conferences - The Manila Times
Collegium Pharmaceutical plans four Miami investor events in March - Stock Titan
Aug EndMonth: What are analysts price targets for Collegium Pharmaceutical IncShort Setup & Growth Oriented Trading Recommendations - baoquankhu1.vn
Collegium Pharmaceutical, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:COLL) 2026-03-01 - Seeking Alpha
A Look At Collegium Pharmaceutical (COLL) Valuation After Mixed Q4 2025 Results And Updated 2026 Guidance - simplywall.st
Collegium Pharmaceutical (NASDAQ:COLL) Lowered to Buy Rating by Wall Street Zen - MarketBeat
Why Collegium Pharmaceutical (COLL) Is Down 7.4% After Reaffirming 2026 Revenue Guidance Despite Earnings Miss - Yahoo Finance
Why Collegium Pharmaceutical (COLL) Stock Is Trading Lower Today - Finviz
Analysts Have Conflicting Sentiments on These Healthcare Companies: Collegium Pharmaceutical (COLL) and Intellia Therapeutics (NTLA) - The Globe and Mail
Relative Strength Alert For Collegium Pharmaceutical - Nasdaq
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q4 2025 Earnings Call Transcript - Insider Monkey
Collegium (COLL) Q4 2025 Earnings Call Transcript - AOL.com
Collegium Pharmaceutical (COLL) Margin Compression To 8.1% Tests Bullish Profitability Narrative - simplywall.st
Collegium Pharmaceutical Earnings Call: Jornay Leads Growth - TipRanks
Collegium Pharmaceutical reports Q4 adjusted EPS $2.04, consensus $2.14 - TipRanks
Collegium Pharmaceutical (NASDAQ:COLL) Announces Quarterly Earnings Results, Misses Expectations By $0.16 EPS - MarketBeat
Collegium Pharmaceutical: Q4 Earnings Snapshot - theheraldreview.com
Collegium Pharmaceutical, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Deep Dive Into Collegium Pharmaceutical Stock: Analyst Perspectives (5 Ratings) - Benzinga
Collegium Pharmaceutical (NASDAQ:COLL) Price Target Lowered to $54.00 at Needham & Company LLC - MarketBeat
Collegium Pharmaceutical (COLL) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Miss Estimates - Nasdaq
Earnings call transcript: Collegium Pharmaceutical Q4 2025 misses EPS forecast - Investing.com Nigeria
Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap Down on Disappointing Earnings - MarketBeat
Collegium Pharmaceutical Q4 Adjusted Earnings, Net Product Revenue Rise - marketscreener.com
Collegium Pharmaceutical Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Collegium Pharmaceutical Q4 Earnings Call Highlights - Yahoo Finance
Collegium Pharmaceutical earnings missed by $0.10, revenue fell short of estimates - Investing.com UK
COLLEGIUM PHARMACEUTICAL ($COLL) Releases Q4 2025 Earnings - Quiver Quantitative
Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for Full Year 2026 - marketscreener.com
Earnings Flash (COLL) Collegium Pharmaceutical, Inc. Posts Q4 Adjusted EPS $2.04 per Share, vs. FactSet Est of $2.14 - marketscreener.com
Collegium Pharmaceutical: Fourth Quarter Financial Overview - Bitget
Collegium Reports Record 2025 Results and Reaffirms Outlook - TipRanks
Collegium Pharmaceutical’s (NASDAQ:COLL) Q4 CY2025 Earnings Results: Revenue In Line With Expectations - Yahoo Finance
COLLEGIUM PHARMACEUTICAL, INC SEC 10-K Report - TradingView
Collegium (NASDAQ: COLL) outlines opioid, ADHD growth and rising generic threats - Stock Titan
Collegium (Nasdaq: COLL) posts record 2025 revenue and EBITDA - Stock Titan
Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results - GlobeNewswire
Collegium Pharmaceutical (COLL) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España
Market Fear: Can Collegium Pharmaceutical Inc be the next market leader2025 Bull vs Bear & Long-Term Capital Growth Strategies - baoquankhu1.vn
Revenue Check: Is BULL stock a hidden gemQuarterly Earnings Summary & AI Driven Price Predictions - baoquankhu1.vn
Collegium Pharmaceutical earnings ahead: Jornay PM in focus By Investing.com - Investing.com South Africa
Collegium Pharmaceutical earnings ahead: Jornay PM in focus - Investing.com
Collegium Pharmaceutical (COLL) Q4 Earnings: What To Expect - Finviz
Collegium Pharmaceutical Inc Azioni (COLL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.18%
1.85%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):